VENLO, the Netherlands, November 6, 2017 /PRNewswire/ --
Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-06-Q3results?sc_lang=en
Contacts Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Dr. Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Email: [email protected] ir.qiagen. com
Public Relations: Dr. Thomas Theuringer Senior Director Public Relations and Digital Communications +49-2103-29-11826 +1-240-686-7425 Email: [email protected] pr.qiagen.com
http://www.twitter.com/qiagen
http://www.facebook.com/QIAGEN
Download the QIAGEN Investor Relations App
Apple: https://itunes.apple.com/us/app/qiagen-investor-relations/id1170201291?mt=8
Android: https://play.google.com/store/apps/details?id=com.theirapp.qiagen&hl=de
SOURCE QIAGEN N.V.
Advertisement
- Solid Q3 2017 performance in line with full-year ambitions:
- Net sales $364.0 million (+7% actual, +7% CER); adjusted net sales $364.4 million (+8% actual, +7% CER vs. +7% CER guidance)
- EPS $0.21; adjusted EPS $0.32 ($0.32 CER), adjusted EPS excluding restructuring charge $0.32 ($0.32 CER vs. $0.32-0.33 CER guidance)
- Nine-month 2017 free cash flow of $146.1 million impacted by $41 million cash restructuring charges
- Solid growth of Sample to Insight portfolio led by QuantiFERON latent TB test growing above 25% CER annual target, complemented by QIAsymphony, human ID / forensics and infectious disease testing portfolio
- $300 million share repurchase commitment completed ahead of end-2017 goal
- New initiative in China to focus on high-growth areas and streamline portfolio
- Reaffirming 2017 adjusted EPS target of $1.25-1.27 CER before restructuring; ~7% CER adjusted net sales growth excluding changes in China portfolio
Advertisement
Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-06-Q3results?sc_lang=en
Contacts Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Dr. Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Email: [email protected] ir.qiagen. com
Public Relations: Dr. Thomas Theuringer Senior Director Public Relations and Digital Communications +49-2103-29-11826 +1-240-686-7425 Email: [email protected] pr.qiagen.com
http://www.twitter.com/qiagen
http://www.facebook.com/QIAGEN
Download the QIAGEN Investor Relations App
Apple: https://itunes.apple.com/us/app/qiagen-investor-relations/id1170201291?mt=8
Android: https://play.google.com/store/apps/details?id=com.theirapp.qiagen&hl=de
SOURCE QIAGEN N.V.